Vertex 611-110

Trial Status: 
Current Trial - Enrolling

Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation


Study with Combination Therapy Ivacaftor and VX-661 for subjects older than 12 years of age with Cystic Fibrosis genotype heterozygote.

Study status: 

Study will only accept subjects from VERTEX 661-108. 


Vertex Pharmaceuticals

Principal Investigator:

 Cori Daines, MD

Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Principal Investigator: 
Research Area: 
Clinical and Population Research